Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis.
Hwi-Yeol YunVincent ChangKendra K RadtkeQianwen WangNatasha StrydomMin Jung ChangRadojka M SavicPublished in: Open forum infectious diseases (2021)
Our results suggest that a 400-mg, twice-daily dose of MOX is an optimal dosing regimen for MDR-TB patients because it provides superior efficacy and safety.
Keyphrases
- multidrug resistant
- end stage renal disease
- mycobacterium tuberculosis
- ejection fraction
- newly diagnosed
- chronic kidney disease
- drug resistant
- acinetobacter baumannii
- gram negative
- prognostic factors
- oxidative stress
- physical activity
- patient reported outcomes
- klebsiella pneumoniae
- electronic health record
- oxide nanoparticles